

## Invalid study design (n = 57)

Abdallah M, Lazarev I, Ariad S, Mermershtain W. Is prostate cancer screening justified in the Bedouin population? *Onkologie* 2009;**32**:260–2.

Akin O, Riedl CC, Ishill NM, Moskowitz CS, Zhang J, Hricak H. Interactive dedicated training curriculum improves accuracy in the interpretation of MR imaging of prostate cancer. *Eur Radiol* 2010;**20**:995–1002.

Altman AL, Resnick MI. Ultrasonographically guided biopsy of the prostate gland. *J Ultrasound Med* 2001;**20**:159–67.

Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, *et al.* Effect of dutasteride on the risk of prostate cancer. *N Engl J Med* 2010;**362**:1192–202.

Awsare NS, Green JS, Aldwinckle B, Hanbury DC, Boustead GB, McNicholas TA. The measurement of psychological distress in men being investigated for the presence of prostate cancer. *Prostate Cancer P D* 2008;**11**:384–9.

Bonekamp D, Jacobs MA, El-Khouli R, Stoianovici D, MacUra KJ. Advancements in MR imaging of the prostate: from diagnosis to interventions. *Radiographics* 2011;**31**:677–703.

Brewster S, Turkeri L, Brausi M, Ravery V, Djavan B. 5A prospective survey of current prostate biopsy practices among oncological urologists. *Can J Urol* 2010;**17**:5071–6.

Chan JK, Chau M. Transrectal ultrasound (TRUS) appearance of carcinoma of prostate in Hong Kong Chinese. *Hong Kong Med J* 1995;**1**:178–9.

Chappell B, McLoughlin J. Technical considerations when obtaining and interpreting prostatic biopsies from men with suspicion of early prostate cancer: Part I. *BJU Int* 2005;**95**:1135–40.

Cheng D, Tempany CM. MR imaging of the prostate and bladder. *Semin Ultrasound CT* 1998;**19**:67–89.

Choi S. The role of magnetic resonance imaging in the detection of prostate cancer. *J Urol* 2011;**186**:1181–2.

Chun FK, Epstein JI, Ficarra V, Freedland SJ, Montironi R, Montorsi F, *et al.* Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature. *Eur Urol* 2010;**58**:851–64.

Ciatto S, Lombardi C, Rubeca T, Zappa M. Predictors of random sextant biopsy outcome in screened men with PSA > 4 ng/ml and a negative sextant biopsy at previous screening. Experience in a population-based screening program in Florence. *Int J Biol Markers* 2004;**19**:89–92.

Cremers RG, Karim-Kos HE, Houterman S, Verhoeven RH, Schroder FH, Van Der Kwast TH, *et al.* Prostate cancer: trends in incidence, survival and mortality in the Netherlands, 1989–2006. *Eur J Cancer* 2010;**46**:2077–87.

Dinan MA, Curtis LH, Hammill BG, Patz EF, Abernethy AP, Shea AM, *et al.* Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999–2006. *JAMA* 2010;**303**:1625–31.

Djavan B, Milani S, Remzi M. Prostate biopsy: who, how and when. An update. *Can J Urol* 2005;**12**:44–8.

Emiliozzi P, Scarpone P, DePaula F, Spigel DR. Impact of biopsy strategy on prostate cancer detection. *J Clin Outcome Manag* 2004;**11**:330–1.

Gallina A, Suardi N, Montorsi F, Capitanio U, Jeldres C, Saad F, *et al.* Mortality at 120 days after prostatic biopsy: A population-based study of 22,175 men. *Int J Cancer* 2008;**123**:647–52.

Gao Z, Wilkin D, Eapen L, Morash C, Wassef Y, Gerig L. Study of prostate delineation referenced against a gold standard created from the visible human data. *Radiother Oncol* 2007;**85**:239–46.

Grabski B, Baeurle L, Loch A, Wefer B, Paul U, Loch T. Computerized transrectal ultrasound of the prostate in a multicenter setup (C-TRUS-MS): detection of cancer after multiple negative systematic random and in primary biopsies. *World J Urol* 2011;**29**:573–9.

Heidenreich A. Consensus criteria for the use of magnetic resonance imaging in the diagnosis and staging of prostate cancer: not ready for routine use. *Eur Urol* 2011;**59**:495–7.

Heijmink SW, Barentsz JO. Contrast-enhanced versus systematic transrectal ultrasound-guided prostate cancer detection: an overview of techniques and a systematic review. *Eur J Radiol* 2007;**63**:310–16.

Ho H, Yuen JSP, Mohan P, Lim EW, Cheng CWS. Robotic transperineal prostate biopsy: pilot clinical study. *Urology* 2011;**78**:1203–8.

Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, *et al.* Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. *Lancet Oncol* 2010;**11**:725–32.

Jager GJ, Severens JL, Thornbury JR, de la Rosette JJ, Ruijs SH, Barentsz JO. Prostate cancer staging: Should MR imaging be used?—A decision analytic approach. *Radiology* 2000;**215**:445–51.

Jones JS. Saturation biopsy for detecting and characterizing prostate cancer. *BJU Int* 2007;**99**:1340–44.

Kahrman G, Donmez H, Mavili E, Ozcan N, Yilmaz SP, Kenan B. Transrectal ultrasound guided multi-core prostate biopsy: pain control: results of 106 patients. *J Clin Ultrasound* 2011;**39**:270–3.

Kwiatkowski M, Huber A, Moschopoulos M, Lehmann K, Wernli M, Hafeli A, *et al.* Screening for prostate cancer: Results of a prospective trial in Canton Aargau, Switzerland. *Swiss Med Wkly* 2004;**134**:580–5.

Labrie F, Candas B, Dupont A, Cusan L, Gomez JL, Suburu RE, *et al.* Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. *Prostate* 1999;**38**:83–91.

Lee G, Attar K, Laniado M, Karim O. Trans-rectal ultrasound guided biopsy of the prostate: nationwide diversity in practice and training in the United Kingdom. *Int Urol Nephrol* 2007;**39**:185–8.

Li H, Sugimura K, Kaji Y, Kitamura Y, Fujii M, Hara I, *et al.* Conventional MRI capabilities in the diagnosis of prostate cancer in the transition zone. *Am J Roentgenol* 2006;**186**:729–42.

Loeb S, Roehl KA, Thaxton C, Cashy JP, Gashti SN, Griffin CR, *et al.* Combined PSA density and biopsy features to predict 'clinically insignificant' prostate cancer. *J Urol* 2007;**177**:338–9.

Marino J, Kaufman A. Prostate cancer visualization from MR imagery and MR spectroscopy. *Comput Graph Forum* 2011;**30**:1051–60.

Melchior SW, Brawer MK. Role of transrectal ultrasound and prostate biopsy. *J Clin Ultrasound* 1996;**24**:463–71.

Ocak I, Bernardo M, Metzger G, Barrett T, Pinto P, Albert PS, et al. Dynamic contrast-enhanced MRI of prostate cancer at 3T: a study of pharmacokinetic parameters. *AJR Am J Roentgenol* 2007;**189**:849.

Onur R, Littrup PJ, Pontes JE, Bianco FJ Jr. Contemporary impact of transrectal ultrasound lesions for prostate cancer detection. *J Urol* 2004;**172**:512–14.

Patel A. Re: Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population. *Eur Urol* 2012;**61**:223–4.

Pinto F, Totaro A, Calarco A, Sacco E, Volpe A, Racioppi M, et al. Imaging in prostate cancer diagnosis: present role and future perspectives. *Urol Int* 2011;**86**:373–82.

Rifkin MD. Prostate cancer: The diagnostic dilemma and the place of imaging in detection and staging. *World J Urol* 1998;**16**:76–80.

Sartor O. Saturation biopsy does not accurately localize tumors. *Nature Rev Urol* 2010;**7**:479–80.

Scattoni V, Sangalli M, Roscigno M, Raber M, Gallina A, Fabbri F, et al. Detection and diagnosis of prostate cancer: what's new. *Arch Ital Urol Androl* 2005;**77**:173–9.

Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. *Eur Urol* 2007;**52**:1309–22.

Schouten MG, Bomers JGR, Yakar D, Huisman H, Rothgang E, Bosboom D, et al. Evaluation of a robotic technique for transrectal MRI-guided prostate biopsies. *Eur Radiol* 2012;**22**:476–83.

Schroder FH, van den Bergh RCN, Wolters T, van Leeuwen PJ, Bangma CH, van der Kwast TH, et al. Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies. *Eur Urol* 2010;**57**:256–66.

Sciarra A, Salciccia S, Panebianco V. Proton spectroscopic and dynamic contrast-enhanced magnetic resonance: A modern approach in prostate cancer imaging. *Eur Urol* 2008;**54**:485–8.

Sfakianos JP, Thorner DA, Dovirak O, Weiss JP, Karanikolas NT. Optimizing prostate cancer detection during biopsy by standardizing the amount of tissue examined per core. *BJU Int* 2011;**108**:1578–81.

Shah N, Sattar A, Benanti M, Hollander S, Cheuck L. Magnetic resonance spectroscopy as an imaging tool for cancer: a review of the literature. *J Am Osteopath Assoc* 2006;**106**:23–7.

Siegelman ES. Magnetic resonance imaging of the prostate. *Semin Roentgenol* 1999;**34**:295–312.

Song JM, Kim CB, Chung HC, Kane RL. Prostate-specific antigen, digital rectal examination and transrectal ultrasonography: a meta-analysis for this diagnostic triad of prostate cancer in symptomatic Korean men. *Yonsei Med J* 2005;**46**:414–24.

Steiner H, Moser P, Hager M, Berger AP, Klocker H, Spranger R, *et al.* Clinical and pathologic features of prostate cancer detected after repeat false-negative biopsy in a screening population. *Prostate* 2004;**58**:277–82.

Susil RC, Coleman JA, Krieger A, Camphausen K, Coleman C, Linehan W, *et al.* Technique and accuracy of a clinical system for transrectal intraprostatic needle placement in a standard 1.5T MRI scanner. *J Urol* 2004;**171**:473–4.

Swanson MG, Vigneron DB, Tran TK, Kurhanewicz J. Magnetic resonance imaging and spectroscopic imaging of prostate cancer. *Cancer Invest* 2001;**19**:510–23.

Tiwari P, Rosen M, Madabhushi A. A hierarchical spectral clustering and nonlinear dimensionality reduction scheme for detection of prostate cancer from magnetic resonance spectroscopy (MRS). *Med Phys* 2009;**36**:3927–39.

Wilson C, Boyd K, Mohammed A, Little B. A single episode of haemospermia can be safely managed in the community. *Int J Clin Pract* 2010;**64**:1436–9.

Wolters T, Roobol MJ, Bangma CH, Schroder FH. Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam). *Eur Urol* 2009;**55**:385–393.

Wu J, Gonzalgo ML. Use of magnetic resonance imaging to accurately detect and stage prostate cancer: the hype and the hope. *J Urol* 2011;**186**:1756–7.

Wu MW, Sevilla EM, Raman L, Consigliere D, Siow WY, Tiong HY. Incidence of complications after transrectal ultrasonography-guided biopsy of the prostate in a local tertiary institution. *Singapore Med J* 2011;**52**:752–7.

## Participants had no previous biopsy or unclear (*n* = 297)

Abdel-Meguid TA, Mosli HA, Al-Maghrabi JA. Prostate inflammation. Association with benign prostatic hyperplasia and prostate cancer. *Saudi Med J* 2009;**30**:1563–7.

Abul FT, Arun N, Abu-Assi MA, Asbeutah AM. Transrectal ultrasound guided biopsy for detecting prostate cancer: can random biopsies be reduced using the 4-dimensional technique? *Int Urol Nephrol* 2007;**39**:517–24.

Aigner F, Pallwein L, Mitterberger M, Pinggera GM, Mikuz G, Horninger W, *et al.* Contrast-enhanced ultrasonography using cadence-contrast pulse sequencing technology for targeted biopsy of the prostate. *BJU Int* 2009;**103**:458–63.

Aigner F, Pallwein L, Schocke M, Lebovici A, Junker D, Schafer G, *et al.* Comparison of real-time sonoelastography with T2-weighted endorectal magnetic resonance imaging for prostate cancer detection. *J Ultrasound Med* 2011;**30**:643–9.

Akin O, Sala E, Moskowitz CS, Kuroiwa K, Ishill NM, Pucar D, *et al.* Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. *Radiology* 2006;**239**:784–92.

Al Abadi H. Fine needle aspiration biopsy vs. ultrasound-guided transrectal random core biopsy of the prostate: comparative investigations in 246 cases. *Acta Cytol* 1997;**41**:981–6.

- Al-Ghazo MA, Ghalayini IF, Matalaka II. Ultrasound-guided transrectal extended prostate biopsy: a prospective study. *Asian J Androl* 2005;**7**:165–9.
- Amirrasouli H, Kazerouni F, Sanadizade M, Sanadizade J, Kamalian N, Jalali M, *et al.* Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population. *Urol J* 2010;**7**:99–104.
- Arnold PM, Niemann TH, Bahnsen RR. Extended sector biopsy for detection of carcinoma of the prostate. *Urol Oncol* 2001;**6**:91–3.
- Arratia-Maqueo JA, Cortes-Gonzalez JR, Garza-Cortes R, Gomez-Guerra LS. Prospective study of prostate cancer's detection rate at our hospital in Northeast Mexican patients with PSA values between 2.6 and 4 ng/ml. *Arch Esp Urol* 2010;**63**:287–90.
- Aslan Y, Tekdogan U, Tuncel A, Uzun MB, Karabulut E, Atan A. Serum dehydroepiandrosterone sulfate usage for early detection of prostate cancer in men with serum prostate specific antigen level between 2.5 and 4.0 ng/ml: A pilot study. *Turk J Med Sci* 2008;**38**:399–404.
- Aus G, Bergdahl S, Hugosson J, Lodding P, Pihl CG, Pileblad E. Outcome of laterally directed sextant biopsies of the prostate in screened males aged 50–66 years. Implications for sampling order. *Eur Urol* 2001;**39**:655–60.
- Auvinen A, Tammela T, Stenman UH, Uusi-Erkila I, Leinonen J, Schroder FH, *et al.* Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in Finland. *Br J Cancer* 1996;**74**:568–72.
- Balaji KC, Fair WR, Feleppa EJ, Porter CR, Tsai H, Liu T, *et al.* Role of advanced 2 and 3-dimensional ultrasound for detecting prostate cancer. *J Urol* 2002;**168**:2422–5.
- Balaji KC, Arnautovic I, Arnautovic A, Neal D. Limited additional lateral biopsies improve the diagnostic accuracy of transrectal ultrasound guided sextant prostate biopsy. *Indian J Urol* 2003;**19**:125–8.
- Barakzai MA, Mubarak M, Kazi JI. Histopathological lesions in transrectal ultrasound guided biopsies of prostate in patients with raised serum prostate specific antigen: a preliminary report. *Nephro-Urol Monthly* 2011;**3**:186–90.
- Barr RG, Memo R, Schaub CR. Shear wave ultrasound elastography of the prostate initial results. *Ultrasound Quarterly* 2012;**28**:13–20.
- Beer AJ, Eiber M, Souvatzoglou M, Holzapfel K, Ganter C, Weirich G, *et al.* Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in (11)C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer. *Molecul Imag Biol* 2011;**13**:352–61.
- Bertaccini A, Franceschelli A, Schiavina R, Manferrari F, Brunocilla E, Marchiori D, *et al.* A novel spectral ultrasonic differentiation method for marking regions of interest in biological tissues. In vivo preliminary results. *Arch Ital Urol Androl* 2007;**79**:108–10.
- Beyersdorff D, Winkel A, Hamm B, Lenk S, Loening SA, Taupitz M. MR imaging-guided prostate biopsy with a closed MR unit at 1.5T: initial results. *Radiology* 2005;**234**:576–81.
- Bigliocchi M, Marini M, Nofroni I, Perugia G, Shahabadi H, Ciccariello M. Prostate cancer detection rate of transrectal ultrasonography, digital rectal examination, and prostate-specific antigen: results of a five-year study of 6- versus 12-core transperineal prostate biopsy. *Minerva Urol Nefrol* 2007;**59**:395–402.

- Bloch N, Degani H, Hruby S, Djavan B, Marberger M, Susani M, *et al.* A novel digitally and perfusion enhanced magnetic resonance imaging (MRI) for prostate cancer diagnosis and staging. *J Urol* 2003;**169**:299–300.
- Bogers HA, Sedelaar JP, Beerlage HP, De La Rosette JJ, Debruyne FM, Wijkstra H, *et al.* Contrast-enhanced three-dimensional power Doppler angiography of the human prostate: correlation with biopsy outcome. *Urology* 1999;**54**:97–104.
- Brajtford JS, Lavery HJ, Nabizada-Pace F, Senaratne P, Samadi DB. Endorectal magnetic resonance imaging has limited clinical ability to preoperatively predict pT3 prostate cancer. *BJU Int* 2011;**107**:1419–24.
- Brossner C, Madersbacher S, Klingler HC, Pycha A, Kuber W, Marberger M. A comparative study of a double-line versus a fan-shaped technique for obtaining transrectal ultrasound-guided biopsies of the prostate. *Eur Urol* 1998;**33**:556–61.
- Brossner C, Madersbacher S, Bayer G, Pycha A, Klingler HC, Maier U. Comparative study of two different TRUS-guided sextant biopsy techniques in detecting prostate cancer in one biopsy session. *Eur Urol* 2000;**37**:65–71.
- Cam K, Ozveri H, Turkeri L, Akdas A. The significance of hypoechoic lesion directed and transition zone biopsies in improving the diagnostic ability in prostate cancer. *Braz J Urol* 2001;**27**:222–6.
- Casciani E, Poletti E, Bertini L, Emiliozzi P, Amini M, Pansadoro V, *et al.* Prostate cancer: evaluation with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. *Radiol Med (Torino)* 2004;**108**:530–41.
- Casciani E, Poletti E, Bertini L, Masselli G, Emiliozzi P, Amini M, *et al.* Contribution of the MR spectroscopic imaging in the diagnosis of prostate cancer in the peripheral zone. *Abdominal Imag* 2007;**32**:796–802.
- Chabanova E, Balslev I, Logager V, Hansen A, Jakobsen H, Kromann-Andersen B, *et al.* Prostate cancer: 1.5T endo-coil dynamic contrast-enhanced MRI and MR spectroscopy-correlation with prostate biopsy and prostatectomy histopathological data. *Eur J Radiol* 2011;**80**:292–6.
- Chang JJ, Shinohara K, Hovey RM, Montgomery C, Presti JC Jr. Prospective evaluation of systematic sextant transition zone biopsies in large prostates for cancer detection. *Urology* 1998;**52**:89–93.
- Chen M, Dang HD, Wang JY, Zhou C, Li SY, Wang WC, *et al.* Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined. *Acta Radiol* 2008;**49**:602–10.
- Chen YT, Chiang PH, Hsu CC. Simultaneous transurethral resection of prostate and prostate needle biopsy in patients with acute urinary retention and elevated prostate specific antigen levels. *Chang Gung Med J* 2009;**32**:417–22.
- Chen SS, Chiu LP, Chen KK. Comparison of transrectal ultrasound-guided biopsy of the prostate and transurethral resection of the prostate for detection of prostate cancer in patients with moderate lower urinary tract symptoms. *JCMA* 2010;**73**:568–72.
- Chen YJ, Pu YS, Chueh SC, Shun CT, Chu WC, Tseng WY. Diffusion MRI predicts transrectal ultrasound biopsy results in prostate cancer detection. *J Magn Reson Imag* 2011;**33**:356–63.

Chiang IN, Chang SJ, Pu YS, Huang KH, Yu HJ, Huang CY. Diagnostic value of finger-guided prostate nodule biopsy combined with systemic random biopsy. *J Formos Med Assoc* 2009;**108**:713–18.

Cho JY, Kim SH, Lee SE. Diffuse prostatic lesions: role of color Doppler and power Doppler ultrasonography. *J Ultrasound Med* 1998;**17**:283–7.

Cho JY, Kim SH, Lee SE. Peripheral hypoechoic lesions of the prostate: evaluation with color and power Doppler ultrasound. *Eur Urol* 2000;**37**:443–8.

Choi MS, Choi YS, Yoon BI, Kim SJ, Cho HJ, Hong SH, *et al*. The clinical value of performing an MRI before prostate biopsy. *Korean J Urol* 2011;**52**:572–7.

Clark TW, Goldenberg L, Cooperberg PL, Wong AD, Singer J. Stratification of prostate-specific antigen level and results of transrectal ultrasonography and digital rectal examination as predictors of positive prostate biopsy. *Can Assoc Radiol J* 1997;**48**:252–8.

Colleselli D, Schilling D, Lichy MP, Hennenlotter J, Vogel UH, Krueger SA, *et al*. Topographical sensitivity and specificity of endorectal coil magnetic resonance imaging for prostate cancer detection. *Urol Int* 2010;**84**:388–94.

Comet-Batlle J, Vilanova-Busquets JC, Saladie-Roig JM, Gelabert-Mas A, Barcelo-Vidal C. The value of endorectal MRI in the early diagnosis of prostate cancer. *Eur Urol* 2003;**44**:201–7.

Cornud F, Belin X, Piron D, Chretien Y, Flam T, Casanova JM, *et al*. Color Doppler-guided prostate biopsies in 591 patients with an elevated serum PSA level: impact on Gleason score for nonpalpable lesions. *Urology* 1997;**49**:709–15.

Cornud F, Hamida K, Flam T, Helenon O, Chretien Y, Thiounn N, *et al*. Endorectal color doppler sonography and endorectal MR imaging features of nonpalpable prostate cancer: correlation with radical prostatectomy findings. *AJR Am J Roentgenol* 2000;**175**:1161–8.

Costouros NG, Coakley FV, Westphalen AC, Qayyum A, Yeh BM, Joe BN, *et al*. Diagnosis of prostate cancer in patients with an elevated prostate-specific antigen level: role of endorectal MRI and MR spectroscopic imaging. *AJR Am J Roentgenol* 2007;**188**:812–16.

Cruz M, Tsuda K, Narumi Y, Kuroiwa Y, Nose T, Kojima Y, *et al*. Characterization of low-intensity lesions in the peripheral zone of prostate on pre-biopsy endorectal coil MR imaging. *Eur Radiol* 2002;**12**:357–65.

Dadkhah F, Safarinejad MR, Amini E, Lashay AR, Baghayee A. Utility of prostate specific antigen density and free to total prostate specific antigen ratio for detecting prostate cancer in Iranian men: a prospective study of 187 cases. *Current Urol* 2010;**4**:1–5.

De La Taille A, Antiphon P, Salomon L, Cherfan M, Porcher R, Hoznek A, *et al*. Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate. *Urology* 2003;**61**:1181–6.

Delongchamps NB, Rouanne M, Flam T, Beuvon F, Liberatore M, Zerbib M, *et al*. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging. *BJU Int* 2011;**107**:1411–18.

deSouza NM, Reinsberg SA, Scurr ED, Brewster JM, Payne GS. Magnetic resonance imaging in prostate cancer: the value of apparent diffusion coefficients for identifying malignant nodules. *Br J Radiol* 2007;**80**:90–5.

Djavan B, Zlotta AR, Ekane S, Remzi M, Kramer G, Roumeguere T, et al. Is one set of sextant biopsies enough to rule out prostate Cancer? Influence of transition and total prostate volumes on prostate cancer yield. *Eur Urol* 2000;**38**:218–24.

Dogan HS, Aytac B, Kordan Y, Gasanov F, Yavascaoglu I. What is the adequacy of biopsies for prostate sampling? *Urol Oncol* 2011;**29**:280–3.

Durkan GC, Sheikh N, Johnson P, Hildreth AJ, Greene DR. Improving prostate cancer detection with an extended-core transrectal ultrasonography-guided prostate biopsy protocol. *BJU International* 2002;**89**:33–9.

Ecke TH, Gerullis H, Heuck CJ, Bartel P, Hallmann S, Koch S, et al. Does a new ultrasound probe change the complication rates of transrectal ultrasound-guided needle biopsies of the prostate? *Anticancer Res* 2010;**30**:3071–6.

Ecke TH, Bartel P, Hallmann S, Koch S, Ruttloff J, Cammann H, et al. Outcome prediction for prostate cancer detection rate with artificial neural network (ANN) in daily routine. *Urol Oncol* 2012;**30**:139–44.

Elabbady AA, Khedr MM. Extended 12-core prostate biopsy increases both the detection of prostate cancer and the accuracy of Gleason score. *Eur Urol* 2006;**49**:49–53.

Emiliozzi P, Longhi S, Scarpone P, Pansadoro A, DePaula F, Pansadoro V. The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen. *J Urol* 2001;**166**:845–50.

Emiliozzi P, Scarpone P, DePaula F, Pizzo M, Federico G, Pansadoro A, et al. The incidence of prostate cancer in men with prostate specific antigen greater than 4.0 ng/ml: a randomized study of 6 versus 12 core transperineal prostate biopsy. *J Urol* 2004;**171**:197–9.

Engelhard K, Hollenbach HP, Deimling M, Kreckel M, Riedl C. Combination of signal intensity measurements of lesions in the peripheral zone of prostate with MRI and serum PSA level for differentiating benign disease from prostate cancer. *Eur Radiol* 2000;**10**:1947–53.

Ferrari FS, Scorzelli A, Megliola A, Drudi FM, Trovarelli S, Ponchietti R. Real-time elastography in the diagnosis of prostate tumor. *J Ultrasound* 2009;**12**:22–31.

Fleshner NE, O'Sullivan M, Premdass C, Fair WR. Clinical significance of small (less than 0.2 cm<sup>3</sup>) hypoechoic lesions in men with normal digital rectal examinations and prostate-specific antigen levels less than 10 ng/ml. *Urology* 1999;**53**:356–8.

Fleshner NE, Fair WR. Indications for transition zone biopsy in the detection of prostatic carcinoma. *J Urol* 1997;**157**:556–8.

Franco OE, Arima K, Yanagawa M, Kawamura J. The usefulness of power Doppler ultrasonography for diagnosing prostate cancer: histological correlation of each biopsy site. *BJU Int* 2000;**85**:1049–52.

Fuganti PE, Tobias-Machado M, Pinto MA, Simardi LH, Wroclawski ER. Twelve core prostate biopsy versus six systematic sextant biopsies. *International Braz J Urol* 2002;**28**:207–13.

Futterer JJ, Heijmink SW, Scheenen TW, Veltman J, Huisman HJ, Vos P, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. *Radiology* 2006;**241**:449–58.



Futterer JJ, Scheenen TW, Heijmink SW, Huisman HJ, Hulsbergen-van de Kaa CA, Witjes JA, *et al.* Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. *Invest Radiol* 2007;**42**:116–22.

Ghafoori M, Varedi P, Hosseini SJ, Asgari M, Shakiba M. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men. *Urology J* 2009;**6**:182–8.

Girouin N, Mege-Lechevallier F, Tonina SA, Bissery A, Rabilloud M, Marechal JM, *et al.* Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? *Eur Radiol* 2007;**17**:1498–509.

Giurgiu CR, Manea C, Crisan N, Bungardean C, Coman I, Dudea SM. Real-time sonoelastography in the diagnosis of prostate cancer. *Med Ultrason* 2011;**13**:5–9.

Goeb K, Engehausen DG, Krause FS, Hollenbach HP, Niedobitek G, Buettner M, *et al.* MRI spectroscopy in screening of prostate cancer. *Anticancer Res* 2007;**27**:687–93.

Gosselaar C, Kranse R, Roobol MJ, Roemeling S, Schroder FH. The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. *Prostate* 2008;**68**:985–93.

Gosselaar C, Roobol MJ, Roemeling S, Wolters T, van Leenders GJ, Schroder FH. The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer. *BJU Int* 2008;**101**:685–90.

Gouhar GK, Taha TF, Allam MN. Detection of prostate cancer: utility of diffusion-weighted MR imaging and 3D MR spectroscopic imaging. *Egypt J Radiol Nuclear Med* 2010;**41**:429–39.

Hahn P, Smith IC, Leboldus L, Littman C, Somorjai RL, Bezabeh T. The classification of benign and malignant human prostate tissue by multivariate analysis of 1H magnetic resonance spectra. *Cancer Res* 1997;**57**:3398–401.

Haffner J, Potiron E, Bouye S, Puech P, Leroy X, Lemaitre L, *et al.* Peripheral zone prostate cancers: location and intraprostatic patterns of spread at histopathology. *Prostate* 2009;**69**:276–82.

Haffner J, Lemaitre L, Puech P, Haber GP, Leroy X, Jones JS, *et al.* Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. *BJU Int* 2011;**108**:1–8.

Haider MA, Van Der Kwast TH, Tanguay J, Evans AJ, Hashmi AT, Lockwood G, *et al.* Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. *AJR Am J Roentgenol* 2007;**189**:323–8.

Halpern EJ, Strup SE. Using gray-scale and color and power Doppler sonography to detect prostatic cancer. *AJR Am J Roentgenol* 2000;**174**:623–7.

Halpern EJ, Rosenberg M, Gomella LG. Prostate cancer: contrast-enhanced US for detection. *Radiology* 2001;**219**:219–25.

Halpern EJ, Frauscher F, Rosenberg M, Gomella LG. Directed biopsy during contrast-enhanced sonography of the prostate. *AJR Am J Roentgenol* 2002;**178**:915–19.

Halpern EI, Frauscher F, Strup SE, Nazarian LN, O’Kane P, Gomella LG. Prostate: High-frequency doppler US imaging for cancer detection. *Radiology* 2002;**225**:71–7.

Hara N, Okuizumi M, Koike H, Kawaguchi M, Bilim V. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. *Prostate* 2005;**62**:140–7.

Hara R, Jo Y, Fuji T, Kondo N, Yokoyama T, Miyaji Y, *et al.* Optimal approach for prostate cancer detection as initial biopsy: Prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy. *Urology* 2008;**71**:191–5.

Hasumi M, Suzuki K, Oya N, Ito K, Kurokawa K, Fukabori Y, *et al.* MR spectroscopy as a reliable diagnostic tool for localization of prostate cancer. *Anticancer Res* 2002;**22**:1205–8.

Hasumi M, Suzuki K, Taketomi A, Matsui H, Yamamoto T, Ito K, *et al.* The combination of multi-voxel MR spectroscopy with MR imaging improve the diagnostic accuracy for localization of prostate cancer. *Anticancer Res* 2003;**23**:4223–7.

Heijmink SW, Futterer JJ, Hambroek T, Takahashi S, Scheenen TW, Huisman HJ, *et al.* Prostate cancer: body-array versus endorectal coil MR imaging at 3T – comparison of image quality, localization, and staging performance. *Radiology* 2007;**244**:184–95.

Heman-Ackah CA, Festenstein JB, Hibbert P, Harvey DJ, Bunce CJ, Gelister JS. Experience with an assay for prostate-specific antigen and transrectal ultrasonography in the diagnosis of prostate cancer. *Br J Urol* 1997;**79**:439–44.

Henderson J, Ghani KR, Cook J, Fahey M, Schalken J, Thilagarajah R. The role of PCA3 testing in patients with a raised prostate-specific antigen level after Greenlight photoselective vaporization of the prostate. *J Endourol* 2010;**24**:1821–4.

Hom JJ, Coakley FV, Simko JP, Qayyum A, Lu Y, Schmitt L, *et al.* Prostate cancer: endorectal MR imaging and MR spectroscopic imaging – distinction of true-positive results from chance-detected lesions. *Radiology* 2006;**238**:192–9.

Hosseini SY, Moharramzadeh M, Ghadian AR, Hooshyar H, Lashay AR, Safarinejad MR. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran. *Int J Urol* 2007;**14**:406–11.

Hua L, Qiao D, Xu B, Feng N, Cheng G, Zhang J, *et al.* Clinical and pathological characteristics of screen-detected versus clinically diagnosed prostate cancer in Nanjing, China. *Med Oncol* 2011;**28**:357–64.

Hwang SI, Lee HJ, Cho JY, Kim SH, Lee SE, Byun SS, *et al.* Should transition zone biopsies be added to 12-core systematic biopsies of the prostate? *J Clin Ultrasound* 2009;**37**:281–4.

Inahara M, Suzuki H, Nakamachi H, Kamiya N, Shimbo M, Komiya A, *et al.* Clinical evaluation of transrectal power doppler imaging in the detection of prostate cancer. *Int Urol Nephrol* 2004;**36**:175–80.

Ishimura T, Sakai I, Hara I, Eto H, Miyake H. Clinical outcome of transrectal ultrasound-guided prostate biopsy, targeting eight cores, for detecting prostate cancer in Japanese men. *Int J Clin Oncol* 2004;**9**:47–50.

Ishizuka O, Mimura Y, Oguchi T, Kawakami M, Nishizawa O. Importance of transition zone prostate biopsies in patients with gray-zone PSA levels undergoing the ultrasound-guided systematic ten-biopsy regimen for the first time. *Urol Int* 2005;**74**:23–6.

Ito K, Ichinose Y, Kubota Y, Imai K, Yamanaka H. Clinicopathological features of prostate cancer detected by transrectal ultrasonography-guided systematic six-sextant biopsy. *Int J Urol* 1997;**4**:474–9.

Ito H, Kamoi K, Yokoyama K, Yamada K, Nishimura T. Visualization of prostate cancer using dynamic contrast-enhanced MRI: comparison with transrectal power Doppler ultrasound. *Br J Radiol* 2003;**76**:617–24.

Iwazawa J, Mitani T, Sassa S, Ohue S. Prostate cancer detection with MRI: is dynamic contrast-enhanced imaging necessary in addition to diffusion-weighted imaging? *Diagnos Intervention Radiol* 2011;**17**:243–8.

Jeong H, Jeong BC, Kwak C, Lee E, Lee SE, Kim TB. A comparison of prostate cancer detection rates by 12 or 6 core biopsy at different prostate-specific antigen densities in Korean men. *World J Urol* 2008;**26**:395–400.

Jeong IG, Kim JK, Cho KS, You D, Song C, Hong JH, *et al.* Diffusion-weighted magnetic resonance imaging in patients with unilateral prostate cancer on extended prostate biopsy: predictive accuracy of laterality and implications for hemi-ablative therapy. *J Urol* 2010;**184**:1963–9.

Kaji Y, Kurhanewicz J, Hricak H, Sokolov DL, Huang LR, Nelson SJ, *et al.* Localizing prostate cancer in the presence of postbiopsy changes on MR images: role of proton MR spectroscopic imaging. *Radiology* 1998;**206**:785–90.

Kajihara H, Hayashida Y, Murakami R, Katahira K, Nishimura R, Hamada Y, *et al.* Usefulness of diffusion-weighted imaging in the localization of prostate cancer. *Int J Radiat Oncol Biol Phys* 2009;**74**:399–403.

Kamoi K, Okihara K, Ochiai A, Ukimura O, Mizutani Y, Kawauchi A, *et al.* The utility of transrectal real-time elastography in the diagnosis of prostate cancer. *Ultrasound Med Biol* 2008;**34**:1025–32.

Kapoor A, Kapoor A, Mahajan G, Sidhu BS. Real-time elastography in the detection of prostate cancer in patients with raised PSA level. *Ultrasound Med Biol* 2011;**37**:1374–81.

Karaman CZ, Unsal A, Akdilli A, Taskin F, Erol H. The value of contrast enhanced power Doppler ultrasonography in differentiating hypoechoic lesions in the peripheral zone of prostate. *Eur J Radiol* 2005;**54**:148–55.

Katahira K, Takahara T, Kwee TC, Oda S, Suzuki Y, Morishita S, *et al.* Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: evaluation in 201 cases with histopathological correlation. *Eur Radiol* 2011;**21**:188–96.

Kawakami S, Yamamoto S, Numao N, Ishikawa Y, Kihara K, Fukui I. Direct comparison between transrectal and transperineal extended prostate biopsy for the detection of cancer. *Int J Urol* 2007;**14**:719–24.

Kefi A, Irer B, Ozdemir I, Tuna B, Goktay Y, Yorukoglu K, *et al.* Predictive value of the international prostate symptom score for positive prostate needle biopsy in the low-intermediate prostate-specific antigen range. *Urol Int* 2005;**75**:222–6.

Kim JW, Lee HY, Hong SJ, Chung BH. Can a 12 core prostate biopsy increase the detection rate of prostate cancer versus 6 core?: a prospective randomized study in Korea. *Yonsei Med J* 2004;**45**:671–5.

Kim JK, Hong SS, Choi YJ, Park SH, Ahn H, Kim CS, *et al.* Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. *J Magn Reson Imag* 2005;**22**:639–46.

Kim CK, Park BK, Kim B. Localization of prostate cancer using 3T MRI: comparison of T2-weighted and dynamic contrast-enhanced imaging. *J Comput Assist Tomogr* 2006;**30**:7–11.

Kim CK, Park BK, Han JJ, Kang TW, Lee HM. Diffusion-weighted imaging of the prostate at 3T for differentiation of malignant and benign tissue in transition and peripheral zones: Preliminary results. *J Comput Assist Tomogr* 2007;**31**:449–54.

Kim CK, Park BK, Lee HM, Kwon GY. Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results. *Invest Radiol* 2007;**42**:842–7.

Kim CK, Park BK, Kim B. High-b-value diffusion-weighted imaging at 3T to detect prostate cancer: comparisons between b values of 1,000 and 2,000 s/mm<sup>2</sup>. *Am J Roentgenol* 2010;**194**:W33–7.

Kim DK, Kim SJ, Moon HS, Park SY, Kim YT, Choi HY, *et al*. The role of TURP in the detection of prostate cancer in BPH patients with previously negative prostate biopsy. *Korean J Urol* 2010;**51**:313–17.

Kim HS, Jeon SS, Choi JD, Kim W, Han DH, Jeong BC, *et al*. Detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/ml. *Urology* 2010;**76**:919–22.

Kimura G, Nishimura T, Kimata R, Saito Y, Yoshida K. Random systematic sextant biopsy versus power doppler ultrasound-guided target biopsy in the diagnosis of prostate cancer: positive rate and clinicopathological features. *J Nippon Med Sch* 2005;**72**:262–9.

Kitajima K, Kaji Y, Fukabori Y, Yoshida K, Suganuma N, Sugimura K. Prostate cancer detection with 3T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. *J Magn Reson Imag* 2010;**31**:625–31.

Kjellman A, Akre O, Norming U, Tornblom M, Gustafsson O. 15-year follow-up of a population based prostate cancer screening study. *J Urol* 2009;**181**:1615–21.

Klijn S, De V, De M, Villeirs GM. Comparison of qualitative and quantitative approach to prostate MR spectroscopy in peripheral zone cancer detection. *Eur J Radiol* 2012;**81**:411–16.

Kobayashi T, Nishizawa K, Ogura K, Mitsumori K, Ide Y. Detection of prostate cancer in men with prostate-specific antigen levels of 2.0 to 4.0 ng/ml equivalent to that in men with 4.1 to 10.0 ng/ml in a Japanese population. *Urology* 2004;**63**:727–31.

Kokeny GP, Cerri GG, de Oliveira Cerri LM, de BN. Correlations among prostatic biopsy results, transrectal ultrasound findings and PSA levels in diagnosing prostate adenocarcinoma. *Eur J Ultrasound* 2000;**12**:103–13.

Konig K, Scheipers U, Pesavento A, Lorenz A, Ermert H, Senge T. Initial experiences with real-time elastography guided biopsies of the prostate. *J Urol* 2005;**174**:115–17.

Kozlowski P, Chang SD, Jones EC, Berean KW, Chen H, Goldenberg SL. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis: correlation with biopsy and histopathology. *J Magn Reson Imag* 2006;**24**:108–13.

Kozlowski P, Chang SD, Meng R, Madler B, Bell R, Jones EC, *et al*. Combined prostate diffusion tensor imaging and dynamic contrast enhanced MRI at 3T: quantitative correlation with biopsy. *Magn Reson Imaging* 2010;**28**:621–8.

Kravchick S, Cytron S, Peled R, Altshuler A, Ben-Dor D. Using gray-scale and two different techniques of color Doppler sonography to detect prostate cancer. *Urology* 2003;**61**:977–81.

Kravchick S, Cytron S, Peled R, London D, Sibi Y, Ben-Dor D. Optimal combinations for detection of prostate cancer: Systematic sextant and laterally directed biopsies versus systematic sextant and color doppler-targeted biopsies. *Urology* 2004;**63**:301–5.

Kravchick S, Cytron S, Stepnov E, Ben-Dor D, Kravchenko Y, Peled R. 7 to 10 years' follow-up of 573 patients with elevated prostate-specific antigen (> 4 ng/ml) or/and suspected rectal examination: biopsies protocol and follow-up guides. *J Endourol* 2009;**23**:1007–13.

Kubota Y, Kamei S, Nakano M, Ehara H, Deguchi T, Tanaka O. The potential role of prebiopsy magnetic resonance imaging combined with prostate-specific antigen density in the detection of prostate cancer. *Int J Urol* 2008;**15**:322–6.

Kuligowska E, Barish MA, Fenlon HM, Blake M. Predictors of prostate carcinoma: Accuracy of gray-scale and color Doppler US and serum markers. *Radiology* 2001;**220**:757–64.

Kumar V, Jagannathan NR, Kumar R, Das SC, Jindal L, Thulkar S, et al. Correlation between metabolite ratios and ADC values of prostate in men with increased PSA level. *Magn Reson Imaging* 2006;**24**:541–8.

Kumar V, Jagannathan NR, Kumar R, Thulkar S, Gupta SD, Hemal AK, et al. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4–10 ng/ml. *NMR Biomed* 2007;**20**:11–20.

Kumar V, Jagannathan NR, Kumar R, Nayyar R, Thulkar S, Gupta SD, et al. Potential of (1)H MR spectroscopic imaging to segregate patients who are likely to show malignancy of the peripheral zone of the prostate on biopsy. *J Magn Reson Imag* 2009;**30**:842–8.

Kurita Y, Ushiyama T, Suzuki K, Fujita K, Kawabe K. PSA value adjusted for the transition zone volume in the diagnosis of prostate cancer. *Int J Urol* 1996;**3**:367–72.

Lan SK, Tsai YS, Lin YH, Tzai TS. Diagnostic performance of a random versus lesion-directed biopsy of the prostate from transrectal ultrasound: results of a 5-year consecutive clinical study in one institution in South Taiwan. *J Ultrasound Med* 2007;**26**:11–17.

Langer DL, van der Kwast TH, Evans AJ, Trachtenberg J, Wilson BC, Haider MA. Prostate Cancer Detection With Multi-parametric MRI: Logistic Regression Analysis of Quantitative T2, Diffusion-Weighted Imaging, and Dynamic Contrast-Enhanced MRI. *J Magn Reson Imag* 2009;**30**:327–34.

Latchamsetty KC, Kim J, Porter CR. Prostate specific antigen remains an independent predictor of cancer at prostate biopsy in black American men but not in white men: results from a consecutive series of 914 men. *J Urol* 2006;**175**:913–17.

Lavoipierre AM, Snow RM, Frydenberg M, Gunter D, Reisner G, Royce PL, et al. Prostatic cancer: Role of color doppler imaging in transrectal sonography. *Am J Roentgenol* 1998;**171**:205–10.

Lawrentschuk N, Toi A, Lockwood GA, Evans A, Finelli A, O'Malley M, et al. Operator is an independent predictor of detecting prostate cancer at transrectal ultrasound guided prostate biopsy. *J Urol* 2009;**182**:2659–63.

Lawrentschuk N, Lockwood G, Davies P, Evans A, Sweet J, Toi A, *et al.* Predicting prostate biopsy outcome: artificial neural networks and polychotomous regression are equivalent models. *Int Urol Nephrol* 2011;**43**:23–30.

Lecuona A, Heyns CF. A prospective, randomized trial comparing the Vienna nomogram to an eight-core prostate biopsy protocol. *BJU Int* 2011;**108**:204–8.

Lee HJ, Kim KG, Lee SE, Byun SS, Hwang SI, Jung SI, *et al.* Role of transrectal ultrasonography in the prediction of prostate cancer: artificial neural network analysis. *J Ultrasound Med* 2006;**25**:815–21.

Leewansangtong S, Tantiwong A, Ratanarapee S, Nualyong C, Soontrapa S. The risks of prostate cancer detection by transrectal ultrasound guide biopsy in Thai men with abnormal prostatic-specific antigen or abnormal digital rectal examination. *J Med Assoc Thai* 2000;**83**:1519–24.

Lemaitre L, Puech P, Poncelet E, Bouye S, Leroy X, Biserte J, *et al.* Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings. *Eur Radiol* 2009;**19**:470–80.

Li H, Yan W, Zhou Y, Ji Z, Chen J. Transperineal ultrasound-guided saturation biopsies using 11-region template of prostate: report of 303 cases. *Urology* 2007;**70**:1157–61.

Lim HK, Kim JK, Kim KA, Cho KS. Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection – a multireader study. *Radiology* 2009;**250**:145–51.

Linden RA, Trabulsi EJ, Forsberg F, Gittens PR, Gomella LG, Halpern EJ. Contrast enhanced ultrasound flash replenishment method for directed prostate biopsies. *J Urol* 2007;**178**:2354–8.

Liu X, Yetik IS. Automated prostate cancer localization without the need for peripheral zone extraction using multiparametric MRI. *Med Phys* 2011;**38**:2986–94.

Loch T, Eppelmann U, Lehmann J, Wullich B, Loch A, Stockle M. Transrectal ultrasound guided biopsy of the prostate: random sextant versus biopsies of sono-morphologically suspicious lesions. *World J Urol* 2004;**22**:357–60.

Lodding P, Aus G, Bergdahl S, Frosing R, Lilja H, Pihl CG, *et al.* Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/ml. Prostate specific antigen. *J Urol* 1998;**159**:899–903.

Lodeta B, Benko G, Car S, Filipan Z, Stajcar D, Dujmovic T. Prostate specific antigen density can help avoid unnecessary prostate biopsies at prostate specific antigen range of 4–10 ng/ml. *Acta Clin Croat* 2009;**48**:153–5.

Lokuhetty MD, Wijesinghe HD, Abeysuriya DT, Samarasinghe UC, Perera ND. Trans rectal ultra sound guided prostate biopsies: a single centre experience in Sri Lanka. *Ceylon Med J* 2009;**54**:6–9.

Lopez-Saez J-B, Otero M, Villar MD, Penuelas AL, Navarro PR, Moreira PG, *et al.* Diagnostic methods in the detection of prostate cancer: prospective observational study. *Curr Med Imag Rev* 2007;**3**:27–35.

Maeda H, Arai Y, Ishitoya S, Okubo K, Aoki Y, Okada T. Prostate specific antigen adjusted for the transition zone volume as an indicator of prostate cancer. *J Urol* 1997;**158**:2193–6.

Malik R, Pandya VK, Naik D. Transrectal ultrasonography for evaluation of various benign and malignant prostatic lesions and their histopathological correlation. *Indian J Radiol Imag* 2004;**14**:155–7.

- Manenti G, Squillaci E, Carlini M, Mancino S, Di RM, Simonetti G. Magnetic resonance imaging of the prostate with spectroscopic imaging using a surface coil. Initial clinical experience. *Radiol Med* 2006;**111**:22–32.
- Manseck A, Guhr K, Hakenberg O, Rossa K, Wirth MP. Clinical significance of the echogenicity in prostatic ultrasound findings in the detection of prostatic carcinoma. *Onkologie* 2000;**23**:151–6.
- Mariappan P, Chong WL, Sundram M, Mohamed SR. Increasing prostate biopsy cores based on volume vs the sextant biopsy: a prospective randomized controlled clinical study on cancer detection rates and morbidity. *BJU Int* 2004;**94**:307–10.
- Martin E, Lujan M, Sanchez E, Herrero A, Paez A, Berenguer A. Final results of a screening campaign for prostate cancer. *Eur Urol* 1999;**35**:26–31.
- Maruyama K, Mizuuchi N, Moroi T, Imura C, Isobe I, Usagawa T, et al. Diffusion-weighted MR Imaging and (1)H MR spectroscopy for studying prostate cancer at 3T without an endorectal coil. *Information* 2009;**12**:193–208.
- Matsubara A, Mutaguchi K, Yasumoto H, Takeshima Y, Teishima J, Seki M, et al. Transrectal ultrasound-guided 10-core biopsy of the prostate for Japanese patients. *Hiroshima J Med Sci* 2006;**55**:65–70.
- Matveev VB. Screening of prostate cancer. Is it needed? Russian experience. *Arch Ital Urol Androl* 2006;**78**:149–51.
- Mazaheri Y, Hricak H, Fine SW, Akin O, Shukla-Dave A, Ishill NM, et al. Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume. *Radiology* 2009;**252**:449–57.
- Megwalu II, Ferguson GG, Wei JT, Mouraviev V, Polascik TJ, Taneja S, et al. Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer. *BJU Int* 2008;**102**:546–50. [Erratum published in *BJU Int* 2009;**104**:284.]
- Mettlin C, Murphy GP, Babaian RJ, Chesley A, Kane RA, Littrup PJ, et al. The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project. *Cancer* 1996;**77**:150–9.
- Mettlin CJ, Murphy GP, Babaian RJ, Chesley A, Kane RA, Littrup PJ, et al. Observations on the early detection of prostate cancer from the American Cancer Society National Prostate Cancer Detection Project. *Cancer* 1997;**80**:1814–17.
- Miao H, Fukatsu H, Ishigaki T. Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging. *Eur J Radiol* 2007;**61**:297–302.
- Minagawa T, Murata Y, Uehara T, Imamura T, Ishizuka O. Impact of high-consistency area evaluated under hand-operated transrectal compression using a sonographic probe on prostate cancer detection: clinicopathological analysis. *Int J Urol* 2010;**17**:876–80.
- Mitterberger M, Aigner F, Pinggera GM, Steiner E, Rehder P, Ulmer H, et al. Contrast-enhanced colour Doppler-targeted prostate biopsy: correlation of a subjective *BJU Int* 2010;**106**:1315–17.
- Miyagawa T, Tsutsumi M, Matsumura T, Kawazoe N, Ishikawa S, Shimokama T, et al. Real-time elastography for the diagnosis of prostate cancer: evaluation of elastographic moving images. *Jpn J Clin Oncol* 2009;**39**:394–8.

Miyake H, Harada K, Inoue TA, Takenaka A, Hara I, Fujisawa M. Additional sampling of dorsal apex on systematic prostate biopsy: impact on early detection of prostate cancer. *Urology* 2007;**69**:738–42.

Mkinen T, Auvinen A, Hakama M, Stenman UH, Tammela TL. Acceptability and complications of prostate biopsy in population-based PSA screening versus routine clinical practice: a prospective, controlled study. *Urology* 2002;**60**:846–50.

Morakkabati-Spitz N, Bastian PJ, Gieseke J, Traber F, Kuhl CK, Wattjes MP, et al. MR imaging of the prostate at 3.0T with external phased array coil – preliminary results. *Eur J Med Res* 2008;**13**:287–91.

Mortimer AM, Ridley N, Cook JL. The influence of ultrasound probe orientation on prostate cancer detection rate during transrectal ultrasonography-guided prostate biopsy. *J Endourol* 2010;**24**:2075–81.

Moslemi MK, Lotfi F, Tahvildar SA. Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience. *Cancer Manag Res* 2011;**3**:227–31.

Moussa AS, Meshref A, Schoenfield L, Masoud A, Abdel-Rahman S, Li J, et al. Importance of additional 'extreme' anterior apical needle biopsies in the initial detection of prostate cancer. *Urology* 2010;**75**:1034–9.

Mullerad M, Hricak H, Kuroiwa K, Pucar D, Chen HN, Kattan MW, et al. Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. *J Urol* 2005;**174**:2158–63.

Nagarajan R, Margolis D, McClure T, Raman S, Thomas MA. Role of endorectal magnetic resonance spectroscopic imaging in two different Gleason scores in prostate cancer. *Med Princ Pract* 2011;**20**:444–8.

Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. *J Urol* 2010;**183**:963–8.

Namimoto T, Morishita S, Saitoh R, Kudoh J, Yamashita Y, Takahashi M. The value of dynamic MR imaging for hypointensity lesions of the peripheral zone of the prostate. *Comput Med Imag Graph* 1998;**22**:239–45.

Narayanaswamy A, Abul F, Mathew TC. Detection rate and clinical pattern of prostate cancer in Kuwait: a single-center experience. *Med Princ Pract* 2011;**20**:34–8.

Natarajan S, Marks LS, Margolis DJ, Huang J, MacAiran ML, Lieu P, et al. Clinical application of a 3D ultrasound-guided prostate biopsy system. *Urol Oncol* 2011;**29**:334–42.

Naughton CK, Miller DC, Mager DE, Ornstein DK, Catalona WJ. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. *J Urol* 2000;**164**:388–92.

Nelson ED, Slotoroff CB, Gomella LG, Halpern EJ. Targeted biopsy of the prostate: the impact of color Doppler imaging and elastography on prostate cancer detection and Gleason score. *Urology* 2007;**70**:1136–40.

Ng LG, Yip S, Tan PH, Yuen J, Lau W, Cheng C. Improved detection rate of prostate cancer using the 10-core biopsy strategy in Singapore. *Asian J Surg* 2002;**25**:238–43.

Ngugi PM, Byakika B. Histology of specimens taken by prostatectomy and needle biopsy. *East Afr Med J* 2007;**84**:363–6.



- Nishida S, Kinoshita H, Mishima T, Kurokawa H, Sakaida N, Matsuda T. Prostate cancer detection by prebiopsy 3.0-Tesla magnetic resonance imaging. *Int J Urol* 2011;**18**:653–8.
- Norberg M, Holmberg L, Busch C, Haggman M, Egevad L, Magnusson A. Multiple transrectal ultrasound-guided biopsies for the detection of prostate cancer and determination of tumor volume, grade, and seminal vesicle invasion. *Eur Radiol* 1996;**6**:56–61.
- Norberg M, Egevad L, Holmberg L, Sparen P, Norlen BJ, Busch C. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. *Urology* 1997;**50**:562–6.
- Novis MI, Baroni RH, Cerri LM, Mattedi RL, Buchpiguel CA. Clinically low-risk prostate cancer: evaluation with transrectal doppler ultrasound and functional magnetic resonance imaging. *Clinics* 2011;**66**:27–34.
- O'Brien BA, Brown AL, Shannon T, Cohen RJ. Prostate biopsy in Western Australia 1998–2004. *Prostate Cancer Prostat Dis* 2010;**13**:263–9.
- O'Connell MJ, Smith CS, Fitzpatrick PE, Keane CO, Fitzpatrick JM, Behan M, *et al*. Transrectal ultrasound-guided biopsy of the prostate gland: value of 12 versus 6 cores. *Abdom Imaging* 2004;**29**:132–6.
- Ogura K, Maekawa S, Okubo K, Aoki Y, Okada T, Oda K, *et al*. Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: correlation with histopathologic results. *Urology* 2001;**57**:721–6.
- Okamura T, Umemoto Y, Yamashita K, Suzuki S, Shirai T, Hashimoto Y, *et al*. Pitfalls with MRI evaluation of prostate cancer detection: comparison of findings with histopathological assessment of retropubic radical prostatectomy specimens. *Urol Int* 2006;**77**:301–6.
- Okihara K, Kojima M, Nakanouchi T, Okada K, Miki T. Transrectal power Doppler imaging in the detection of prostate cancer. *BJU Int* 2000;**85**:1053–7.
- Okihara K, Miki T, Joseph BR. Clinical efficacy of prostate cancer detection using power doppler imaging in American and Japanese men. *J Clin Ultrasound* 2002;**30**:213–21.
- Okihara K, Kamoi K, Ochiai A, Ukimura O, Ushijima S, Mizutani Y, *et al*. Can real-time transrectal elastography in combination with power doppler sonography enhance prostate cancer detection? *J Urol* 2007;**177**:564–5.
- Palumbo F, Bettocchi C, Spilotros M, Vavallo A, Palazzo S, Ditunno P, *et al*. A prospective study on patient's erectile function following transrectal ultrasound guided prostate biopsy. *Arch Ital Urol Androl* 2010;**82**:265–8.
- Park JY, Yoon S, Park MS, Cho DY, Park HS, Moon DG, *et al*. Initial biopsy outcome prediction in Korean patients-comparison of a noble web-based Korean prostate cancer risk calculator versus prostate-specific antigen testing. *J Korean Med Sci* 2011;**26**:85–91.
- Passavanti G, Pizzuti V, Bragaglia A, Costantini FM, Paolini R. The association of TR systematic echobiopsy of the prostate with power Doppler (PDU) in borderline PSA patients. *Arch Ital Urol Androl* 2005;**77**:40–2.
- Paul R, Korzinek C, Necknig U, Niesel T, Alschibaja M, Leyh H, *et al*. Influence of transrectal ultrasound probe on prostate cancer detection in transrectal ultrasound-guided sextant biopsy of prostate. *Urology* 2004;**64**:532–6.

Pelzer A, Bektic J, Berger AP, Pallwein L, Halpern EJ, Horninger W, *et al.* Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color doppler targeted and systematic biopsy. *J Urol* 2005;**173**:1926–9.

Pepe P, Aragona F. Prostate needle biopsy: 12 vs. 18 cores: is it necessary? *Urol Int* 2005;**74**:19–22.

Pepe P, Patane D, Panella P, Aragona F. Does the adjunct of echographic contrast medium Levovist improve the detection rate of prostate cancer? *Prostate Cancer Prostat Dis* 2003;**6**:159–62.

Philip J, Ragavan N, DeSouza J, Foster CS, Javle P. Effect of peripheral biopsies in maximising early prostate cancer detection in 8-, 10- or 12-core biopsy regimens. *BJU Int* 2004;**93**:1218–20.

Philip J, Manikandan R, Javle P, Foster CS. Prostate cancer diagnosis: should patients with prostate specific antigen > 10 ng/ml have stratified prostate biopsy protocols? *Canc Detect Prev* 2009;**32**:314–18.

Pickles MD, Gibbs P, Sreenivas M, Turnbull LW. Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0T. *J Magn Reson Imag* 2006;**23**:130–4.

Pinto PA, Chung PH, Rastinehad AR, Baccala AA Jr, Kruecker J, Benjamin CJ, *et al.* Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. *J Urol* 2011;**186**:1281–5.

Presti JC Jr, Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. *J Urol* 2000;**163**:163–6.

Puech P, Betrouni N, Makni N, Dewalle AS, Villers A, Lemaitre L. Computer-assisted diagnosis of prostate cancer using DCE-MRI data: design, implementation and preliminary results. *Int J Computer Assis Radiol Surg* 2009;**4**:1–10.

Puech P, Potiron E, Lemaitre L, Leroy X, Haber GP, Crouzet S, *et al.* Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. *Urology* 2009;**74**:1094–9.

Rabah DM, Arafa MA. Prostate cancer screening in a Saudi population: an explanatory trial study. *Prostate Cancer P D* 2010;**13**:191–4.

Raber M, Scattoni V, Gallina A, Freschi M, De A, Girolamo VD, *et al.* Does the transrectal ultrasound probe influence prostate cancer detection in patients undergoing an extended prostate biopsy scheme? Results of a large retrospective study. *BJU Int* 2012;**109**:672–7.

Ravery V, Billebaud T, Toublanc M, Boccon-Gibod L, Hermieu JF, Moulinier F, *et al.* Diagnostic value of ten systematic TRUS-guided prostate biopsies. *Eur Urol* 1999;**35**:298–303.

Ravery V, Goldblatt L, Royer B, Blanc E, Toublanc M, Boccon-Gibod L. Extensive biopsy protocol improves the detection rate of prostate cancer. *J Urol* 2000;**164**:393–6.

Reinsberg SA, Payne GS, Riches SF, Ashley S, Brewster JM, Morgan VA, *et al.* Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection. *AJR Am J Roentgenol* 2007;**188**:91–8.

Reissigl A, Pointner J, Strasser H, Ennemoser O, Klocker H, Bartsch G. Frequency and clinical significance of transition zone cancer in prostate cancer screening. *Prostate* 1997;**30**:130–5.

Renty P, D'Hauwers K, Van CC, Verheyden B, Gentens P, Wyndaele JJ. Value of transrectal prostatic echography, prostate-specific antigen and rectal examination in the diagnosis of prostate cancer. Relationship with the result of prostatic biopsies. *Acta Urol Belg* 1996;**64**:7–12.

Rochester MA, Griffin S, Chappell B, McLoughlin J. A prospective randomised trial of extended core prostate biopsy protocols utilizing 12 versus 15 cores. *Urol Int* 2009;**83**:155–9.

Rosenkrantz AB, Mannelli L, Kong X, Niver BE, Berkman DS, Babb JS, *et al*. Prostate cancer: Utility of fusion of T2-weighted and high b-value diffusion-weighted images for peripheral zone tumor detection and localization. *J Magn Reson Imag* 2011;**34**:95–100.

Rosenkrantz AB, Neil J, Kong X, Melamed J, Babb JS, Taneja SS, *et al*. Prostate cancer: Comparison of 3D T2-weighted with conventional 2D T2-weighted imaging for image quality and tumor detection. *AJR Am J Roentgenol* 2010;**194**:446–52.

Rouse P, Shaw G, Ahmed HU, Calleary JG, Illing RO, Kirkham AP, *et al*. Pre-biopsy Scattoni V, Raber M, Abdollah F, Roscigno M, Deho F, Angiolilli D, *et al*. Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy. *Eur Urol* 2010;**57**:1–8.

Rouse P, Shaw G, Ahmed HU, Freeman A, Allen C, Emberton M. Multi-parametric magnetic resonance imaging to rule-in and rule-out clinically important prostate cancer in men at risk: a cohort study. *Urol Int* 2011;**87**:49–53.

Roy C, Buy X, Lang H, Saussine C, Jacqmin D. Contrast enhanced color Doppler endorectal sonography of prostate: efficiency for detecting peripheral zone tumors and role for biopsy procedure. *J Urol* 2003;**170**:69–72.

Saito K, Kaminaga T, Muto S, Ide H, Nishio K, Kamiyama Y, *et al*. Clinical efficacy of proton magnetic resonance spectroscopy (1H-MRS) in the diagnosis of localised prostate cancer. *Anticancer Res* 2008;**28**:1899–904.

Sakarya ME, Arslan H, Unal O, Atilla MK, Aydin S. The role of power Doppler ultrasonography in the diagnosis of prostate cancer: a preliminary study. *Br J Urol* 1998;**82**:386–8.

Salomon G, Koellermann J, Thederan I, Chun FKH, Budaues L, Schlomm T, *et al*. Evaluation of prostate cancer detection with ultrasound real-time elastography: a comparison with step section pathological analysis after radical prostatectomy. *Eur Urol* 2008;**54**:1354–62.

Sato C, Naganawa S, Nakamura T, Kumada H, Miura S, Takizawa O, *et al*. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. *J Magn Reson Imag* 2005;**21**:258–62.

Scheenen TW, Heijmink SW, Roell SA, Hulsbergen-van de Kaa CA, Knipscheer BC, Witjes JA, *et al*. Three-dimensional proton MR spectroscopy of human prostate at 3T without endorectal coil: feasibility. *Radiology* 2007;**245**:507–16.

Scheenen TW, Futterer J, Weiland E, van HP, Lemort M, Zechmann C, *et al*. Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study. *Invest Radiol* 2011;**46**:25–33.

Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, *et al*. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging – clinicopathologic study. *Radiology* 1999;**213**:473–80.

Scherr MK, Seitz M, Muller-Lisse UG, Ingrisch M, Reiser MF, Muller-Lisse UL. MR-perfusion (MRP) and diffusion-weighted imaging (DWI) in prostate cancer: quantitative and model-based gadobenate dimeglumine MRP parameters in detection of prostate cancer. *Eur J Radiol* 2010;**76**:359–66.

Schmuecking M, Boltze C, Geyer H, Salz H, Schilling B, Wendt TG, *et al.* Dynamic MRI and CAD vs. choline MRS: where is the detection level for a lesion characterisation in prostate cancer? *Int J Radiat Biol* 2009;**85**:814–24.

Schroder FH, Van DC-K, I, De Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. *J Urology* 2000;**163**:806–12.

Sedelaar JP, van Roermund JG, van Leenders GL, Hulsbergen-van de Kaa CA, Wijkstra H, De La Rosette JJ. Three-dimensional grayscale ultrasound: evaluation of prostate cancer compared with benign prostatic hyperplasia. *Urology* 2001;**57**:914–20.

Seitz M, Gratzke C, Schlenker B, Buchner A, Karl A, Roosen A, *et al.* Contrast-enhanced transrectal ultrasound (CE-TRUS) with cadence-contrast pulse sequence (CPS) technology for the identification of prostate cancer. *Urol Oncol* 2011;**29**:295–301.

Seltzer MA, Shinohara K, Bhargava V, Carroll PR, Presti JC Jr. Comparison of systematic sextant and lesion directed biopsies in prostate cancer detection. *Urol Oncol* 1996;**2**:136–8.

Shigemura K, Arakawa S, Yamanaka K, Kataoka N, Yuien K, Fujisawa M. Significance of lateral biopsy specimens during transrectal ultrasound-guided prostate biopsies in Japanese men. *Int J Urol* 2007;**14**:935–8.

Shigeno K, Igawa M, Shiina H, Wada H, Yoneda T. The role of colour Doppler ultrasonography in detecting prostate cancer. *BJU Int* 2000;**86**:229–33.

Shim HB, Lee SE, Park HK, Ku JH. Histological diagnosis of prostate cancer in Korean men aged 70–79 years. *Jpn J Clin Oncol* 2007;**37**:782–7.

Shimizu T, Nishie A, Ro T, Tajima T, Yamaguchi A, Kono S, *et al.* Prostate cancer detection: the value of performing an MRI before a biopsy. *Acta Radiol* 2009;**50**:1080–8.

Singh M, Shaheen F, Singh B, Khwaja R, Gojwari T, Hussain H. Transrectal ultrasonography of prostate: correlation with histopathology. *JK-Practitioner* 2006;**13**:138–9.

Sinha S, Siriguri SR, Kanakmedala SK, Bikkasani K. Prostate biopsy findings in Indian men: a hospital-based study. *Indian J Canc* 2011;**48**:175–80.

Slongo LE, Sugisawa MC, Ioshii SO, Filho RT, Rocha LC. Efficiency of 6- and 12-punctures biopsies to detect prostate cancer in patients with PSA  $\leq$  10 ng/ml and normal digital rectal examination. *International Braz J Urol* 2003;**29**:24–9.

Smart R. Outcomes of transrectal ultrasound scan of the prostate with sector biopsies for 323 New Zealand men with suspicion of prostate cancer. *N Z Med J* 1999;**112**:465–9.

Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. *Eur Urol* 2010;**58**:831–5.

Spajic B, Eupic H, Tomas D, Stimac G, Kruslin B, Kraus O. The incidence of hyperechoic prostate cancer in transrectal ultrasound-guided biopsy specimens. *Urology* 2007;**70**:734–7.

Sperandeo G, Sperandeo M, Morcaldi M, Caturelli E, Dimitri L, Camagna A. Transrectal ultrasonography for the early diagnosis of adenocarcinoma of the prostate: a new maneuver designed to improve the differentiation of malignant and benign lesions. *J Urol* 2003;**169**:607–10.

Squillaci E, Manenti G, Mancino S, Cariani M, Di RM, Colangelo V, et al. MR spectroscopy of prostate cancer. Initial clinical experience. *J Experiment Clin Cancer Res* 2005;**24**:523–30.

Sung JC, Kabalin JN, Terris MK. Prostate cancer detection, characterization, and clinical outcomes in men aged 70 years and older referred for transrectal ultrasound and prostate biopsies. *Urology* 2000;**56**:295–301.

Suzuki M, Kawakami S, Asano T, Masuda H, Saito K, Koga F, et al. Safety of transperineal 14-core systematic prostate biopsy in diabetic men. *Int J Urol* 2009;**16**:930–5.

Takahashi S, Yamada Y, Homma Y, Horie S, Hosaka Y, Kitamura T. Power Doppler ultrasonography-directed prostate biopsy in men with elevated serum PSA levels: an evaluation of the clinical utility and limitations. *Urology* 2002;**60**:248–52.

Takenaka A, Hara R, Ishimura T, Fujii T, Jo Y, Nagai A, et al. A prospective randomized comparison of diagnostic efficacy between transperineal and transrectal 12-core prostate biopsy. *Prostate Cancer Prostat Dis* 2008;**11**:134–8.

Tamada T, Sone T, Jo Y, Yamamoto A, Yamashita T, Egashira N, et al. Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis. *Radiology* 2008;**248**:531–9.

Tamada T, Sone T, Higashi H, Jo Y, Yamamoto A, Kanki A, et al. Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4–10 ng/ml: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. *AJR Am J Roentgenol* 2011;**197**:664–70.

Tamsel S, Killi R, Hekimgil M, Altay B, Soydan S, Demirpolat G. Transrectal ultrasound in detecting prostate cancer compared with serum total prostate-specific antigen levels. *J Med Imag Radiat Oncol* 2008;**52**:24–8.

Tan H, Gan E, Rekhraj I, Cheng C, Li M, Thng P, et al. Use of prostate specific antigen (PSA) and transrectal ultrasound (TRUS) in the diagnosis of prostate cancer: a local experience. *Ann Acad Med Singapore* 1995;**24**:550–6.

Tanaka N, Samma S, Joko M, Akiyama T, Takewa M, Kitano S, et al. Diagnostic usefulness of endorectal magnetic resonance imaging with dynamic contrast-enhancement in patients with localised prostate cancer: mapping studies with biopsy specimens. *Int J Urol* 1999;**6**:593–9.

Tang J, Yang JC, Li Y, Li J, Shi H. Peripheral zone hypoechoic lesions of the prostate: evaluation with contrast-enhanced gray scale transrectal ultrasonography. *J Ultrasound Med* 2007;**26**:1671–9.

Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. *J Magn Reson Imag* 2007;**25**:146–52.

Tarcan T, Ozveri H, Biren T, Turkeri L, Akdas A. Evaluation of prostate specific antigen density and transrectal ultrasonography-guided biopsies in 100 consecutive patients with a negative digital rectal examination and intermediate serum prostate specific antigen levels. *Int J Urol* 1997;**4**:362–7.

Taverna G, Morandi G, Seveso M, Giusti G, Benetti A, Colombo P, *et al.* Colour Doppler and microbubble contrast agent ultrasonography do not improve cancer detection rate in transrectal systematic prostate biopsy sampling. *BJU Int* 2011;**108**:1723–7.

Terris MK, Pham TQ, Issa MM, Kabalin JN. Routine transition zone and seminal vesicle biopsies in all patients undergoing transrectal ultrasound guided prostate biopsies are not indicated. *J Urol* 1997;**157**:204–6.

Testa C, Schiavina R, Lodi R, Salizzoni E, Corti B, Farsad M, *et al.* Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. *Radiology* 2007;**244**:797–806.

Toi A, Neill MG, Lockwood GA, Sweet JM, Tammsalu LA, Fleshner NE. The continuing importance of transrectal ultrasound identification of prostatic lesions. *J Urol* 2007;**177**:516–20.

Turkbey B, Pinto PA, Mani H, Bernardo M, Pang Y, McKinney YL, *et al.* Prostate cancer: value of multiparametric MR imaging at 3 T for detection – histopathologic correlation. *Radiology* 2010;**255**:89–99.

Turkbey B, Xu S, Kruecker J, Locklin J, Pang Y, Bernardo M, *et al.* Documenting the location of prostate biopsies with image fusion. *BJU Int* 2011;**107**:53–7.

Turkbey B, Xu S, Kruecker J, Locklin J, Pang Y, Shah V, *et al.* Documenting the location of systematic transrectal ultrasound-guided prostate biopsies: correlation with multi-parametric MRI. *Canc Imag* 2011;**11**:31–6.

Uno H, Nakano M, Ehara H, Deguchi T. Indications for extended 14-core transrectal ultrasound-guided prostate biopsy. *Urology* 2008;**71**:23–7.

van der Crujisen-Koeter IW, Vis AN, Roobol MJ, Wildhagen MF, De Koning HJ, Van Der Kwast TH, *et al.* Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. *J Urol* 2005;**174**:121–5.

Vilanova JC, Comet J, Barcelo-Vidal C, Barcelo J, Lopez-Bonet E, Maroto A, *et al.* Peripheral zone prostate cancer in patients with elevated PSA levels and low free-to-total PSA ratio: detection with MR imaging and MR spectroscopy. *Radiology* 2009;**253**:135–43.

Vilanova JC, Barcelo-Vidal C, Comet J, Boada M, Barcelo J, Ferrer J, *et al.* Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer. *AJR Am J Roentgenol* 2011;**196**:W715–22.

Villeirs GM, Oosterlinck W, Vanherreweghe E, De Meerleer GO. A qualitative approach to combined magnetic resonance imaging and spectroscopy in the diagnosis of prostate cancer. *Eur J Radiol* 2010;**73**:352–6.

Villeirs GM, De Meerleer GO, De Visschere PJ, Fonteyne VH, Verbaeys AC, Oosterlinck W. Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients. *Eur J Radiol* 2011;**77**:340–5.

Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localised prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. *J Urol* 2006;**176**:2432–7.

Villers A, Puech P, Leroy X, Biserte J, Fantoni J-C, Lemaitre L. Dynamic contrast-enhanced MRI for preoperative identification of localised prostate cancer. *Eur Urol Suppl* 2007;**6**:525–32.

Vos PC, Hambroek T, Barenstz JO, Huisman HJ. Computer-assisted analysis of peripheral zone prostate lesions using T2-weighted and dynamic contrast enhanced T1-weighted MRI. *Phys Med Biol* 2010;**55**:1719–34.

Vukotic-Maletic V, Cerovic S, Lazic M, Rakovic I. Diagnosis of prostate cancer in Serbia. *J Buon* 2005;**10**:265–9.

Wang R, Chen JJ, Zhou YC, Huang MM, Zhang XR, Miao HD. Evaluation of diffusion-weighted magnetic resonance imaging and contrast-enhanced harmonic ultrasonography in detection and location of prostate transition-zone cancer. *J Int Med Res* 2011;**39**:256–66.

Watanabe M, Hayashi T, Tsushima T, Irie S, Kaneshige T, Kumon H. Extensive biopsy using a combined transperineal and transrectal approach to improve prostate cancer detection. *Int J Urol* 2005;**12**:959–63.

Watanabe H, Kanematsu M, Kondo H, Kako N, Yamamoto N, Yamada T, et al. Preoperative detection of prostate cancer: a comparison with <sup>11</sup>C-choline PET, <sup>18</sup>F-fluorodeoxyglucose PET and MR imaging. *J Magn Reson Imag* 2010;**31**:1151–6.

Weidner AM, Michaely HJ, Lemke A, Breitingner L, Wenz F, Marx A, et al. Value of multiparametric prostate MRI of the peripheral zone. *Z Med Phys* 2011;**21**:198–205.

Weinreb JC, Blume JD, Coakley FV, Wheeler TM, Cormack JB, Sotito CK, et al. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy – results of ACRIN prospective multi-institutional clinicopathologic study. *Radiology* 2009;**251**:122–33.

Westphalen AC, Coakley FV, Qayyum A, Swanson M, Simko JP, Lu Y, et al. Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging. *Radiology* 2008;**246**:177–84.

Wright JL, Ellis WJ. Improved prostate cancer detection with anterior apical prostate biopsies. *Urol Oncol* 2006;**24**:492–5.

Yagci AB, Ozari N, Aybek Z, Duzcan E. The value of diffusion-weighted MRI for prostate cancer detection and localization. *Diagnos Intervent Radiol* 2011;**17**:130–4.

Yakar D, Heijmink SW, Hulsbergen-van de Kaa CA, Huisman H, Barentsz JO, Futterer JJ, et al. Initial results of 3-dimensional 1H-magnetic resonance spectroscopic imaging in the localization of prostate cancer at 3 Tesla: should we use an endorectal coil? *Invest Radiol* 2011;**46**:301–6.

Yamaguchi T, Lee J, Uemura H, Sasaki T, Takahashi N, Oka T, et al. Prostate cancer: a comparative study of <sup>11</sup>C-choline PET and MR imaging combined with proton MR spectroscopy. *Eur J Nucl Med Molecul Imag* 2005;**32**:742–8.

Yamamura J, Salomon G, Buchert R, Hohenstein A, Graessner J, Huland H, et al. Magnetic resonance imaging of prostate cancer: diffusion-weighted imaging in comparison with sextant biopsy. *J Comput Assist Tomogr* 2011;**35**:223–8.

Yang JC, Tang J, Li J, Luo Y, Li Y, Shi H. Contrast-enhanced gray-scale transrectal ultrasound-guided prostate biopsy in men with elevated serum prostate-specific antigen levels. *Acad Radiol* 2008;**15**:1291–7.

Yokomizo Y, Miyoshi Y, Nakaigawa N, Makiyama K, Ogawa T, Yao M, et al. Free PSA/total PSA ratio increases the detection rate of prostate cancer in twelve-core biopsy. *Urol Int* 2009;**82**:280–5.

Yoshimitsu K, Kiyoshima K, Irie H, Tajima T, Asayama Y, Hirakawa M, et al. Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: correlation with stepwise histopathology. *J Magn Reson Imag* 2008;**27**:132–9.

Yu JS, Chung JJ, Hong SW, Chung BH, Kim JH, Kim KW. Prostate cancer: added value of subtraction dynamic imaging in 3T magnetic resonance imaging with a phased-array body coil. *Yonsei Med J* 2008;**49**:765–74.

Yunkai Z, Yaqing C, Ren W, Yongchang Z. Are transition zone biopsies necessary in transrectal ultrasound-guided transperineal prostate biopsy protocol? Results of a Chinese population-based study. *Clin Imaging* 2010;**34**:43–6.

Zelhof B, Lowry M, Rodrigues G, Kraus S, Turnbull L. Description of magnetic resonance imaging-derived enhancement variables in pathologically confirmed prostate cancer and normal peripheral zone regions. *BJU Int* 2009;**104**:621–7.

Zheng XY, Xie LP, Wang YY, Ding W, Yang K, Shen HF, et al. The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4–10 ng/ml. *J Cancer Res Clin Oncol* 2008;**134**:1207–10.

### **Invalid test(s) (n = 18)**

Aigner F, Schäfer G, Steiner E, Jaschke W, Horninger W, Herrmann TRW, et al. Value of enhanced transrectal ultrasound targeted biopsy for prostate cancer diagnosis: a retrospective data analysis. *World J Urol* 2012;**30**:341–6.

Bittner N, Merrick GS, Stewart R, Andreini H, Taubenslag W, Curtis R, et al. Obesity does not correlate with adverse pathologic findings on transperineal template-guided mapping biopsy of the prostate. *Urol Oncol* 2011;**29**:398–404.

Bott SR, Henderson A, Halls JE, Montgomery BS, Laing R, Langley SE. Extensive transperineal template biopsies of prostate: modified technique and results. *Urology* 2006;**68**:1037–41.

Ciatto S, Bonardi R, Lombardi C, Cappelli G, Castagnoli A, D'Agata A, et al. Predicting prostate biopsy outcome by findings at digital rectal examination, transrectal ultrasonography, PSA, PSA density and free-to-total PSA ratio in a population-based screening setting. *Int J Biol Markers* 2001;**16**:179–82.

Grasso-Leanza F, Pepe P, Panella P, Pennisi M. Digito-rectal exploration, PSA and echomotography in the early diagnosis of prostate cancer; our experience with 1185 patients. *Acta Urol It* 1996;**10**:179–83.

Igel TC, Knight MK, Young PR, Wehle MJ, Petrou SP, Broderick GA, et al. Systematic transperineal ultrasound guided template biopsy of the prostate in patients at high risk. *J Urol* 2001;**165**:1575–9.

Kumar R, Nayyar R, Kumar V, Gupta NP, Hemal AK, Jagannathan NR, et al. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study. *Urology* 2008;**72**:859–63.



Loch T. Computerized transrectal ultrasound (C-TRUS) of the prostate: detection of cancer in patients with multiple negative systematic random biopsies. *World J Urol* 2007;**25**:375–80.

Merrick GS, Taubenslag W, Andreini H, Brammer S, Butler WM, Adamovich E, *et al*. The morbidity of transperineal template-guided prostate mapping biopsy. *BJU Int* 2008;**101**:1524–9.

Morgan VA, Kyriazi S, Ashley SE, deSouza NM. Evaluation of the potential of diffusion-weighted imaging in prostate cancer detection. *Acta Radiol* 2007;**48**:695–703.

Perdoná S, Di Lorenzo G, Autorino R, Buonerba C, De Sio M, Setola SV, *et al*. Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection. *Urol Oncol* 2013. doi:10.1016/j.urolonc.2011.07.010

Perrotti M, Han KR, Epstein RE, Kennedy EC, Rabbani F, Badani K, *et al*. Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostatic biopsy: a pilot study. *J Urol* 1999;**162**:1314–17.

Pinkstaff DM, Igel TC, Petrou SP, Broderick GA, Wehle MJ, Young PR. Systematic transperineal ultrasound-guided template biopsy of the prostate: three-year experience. *Urology* 2005;**65**:735–9.

Satoh T, Matsumoto K, Fujita T, Tabata K, Okusa H, Tsuboi T, *et al*. Cancer core distribution in patients diagnosed by extended transperineal prostate biopsy. *Urology* 2005;**66**:114–18.

Sauvain JL, Palascak P, Bourscheid D, Chabi C, Atassi A, Bremon JM, *et al*. Value of power doppler and 3D vascular sonography as a method for diagnosis and staging of prostate cancer. *Eur Urol* 2003;**44**:21–30.

Taira AV, Merrick GS, Galbreath RW, Andreini H, Taubenslag W, Curtis R, *et al*. Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. *Prostate Cancer Prostat Dis* 2010;**13**:71–7.

Takenaka A, Hara R, Hyodo Y, Ishimura T, Sakai Y, Fujioka H, *et al*. Transperineal extended biopsy improves the clinically significant prostate cancer detection rate: a comparative study of 6 and 12 biopsy cores. *Int J Urol* 2006;**13**:10–14.

Taymoorian K, Thomas A, Slowinski T, Khiabanchian M, Stephan C, Lein M, *et al*. Transrectal broadband-Doppler sonography with intravenous contrast medium administration for prostate imaging and biopsy in men with an elevated PSA value and previous negative biopsies. *Anticancer Res* 2007;**27**:4315–20.

### Reference standard not appropriate (n = 2)

Labanaris AP, Engelhard K, Zugor V, Witt JH, Kuhn R. Inapparent tumor on endorectal multimodality magnetic resonance imaging of prostate: should we perform a biopsy? *Urology* 2011;**78**:116–20.

Remzi M, Dobrovits M, Reissigl A, Ravery V, Waldert M, Wiunig C, *et al*. Can Power Doppler enhanced transrectal ultrasound guided biopsy improve prostate cancer detection on first and repeat prostate biopsy? *Eur Urol* 2004;**46**:451–6.

### Diagnostic outcomes not reported (n = 70)

Ahmed M. Prostate cancer diagnosis in a resource-poor setting: the changing role of digital rectal examination. *Trop Doct* 2011;**41**:141–3.

Anastasiadis AG, Lichy MP, Nagele U, Kuczyk MA, Merseburger AS, Hennenlotter J, *et al.* MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. *Eur Urol* 2006;**50**:738–48.

Barqawi AB, Rove KO, Gholizadeh S, O'Donnell CI, Koul H, Crawford ED. The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer. *J Urol* 2011;**186**:80–5.

Basillote JB, Armenakas NA, Hochberg DA, Fracchia JA. Influence of prostate volume in the detection of prostate cancer. *Urology* 2003;**61**:167–71.

Borboroglu PG, Comer SW, Riffenburgh RH, Amling CL. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. *J Urol* 2000;**163**:158–62.

Chen VH, Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, *et al.* Utility of a 3-dimensional transrectal ultrasound-guided prostate biopsy system for prostate cancer detection. *Technol Cancer Res Treat* 2009;**8**:99–104.

Ching CB, Zaytoun O, Moussa AS, Li J, Avallone A, Jones JS. Type of transrectal ultrasonography probe influences prostate cancer detection rates on repeat prostate biopsy. *BJU Int* 2011;**110**:E46.

De NC, Trucchi A, Miano R, Stoppacciaro A, Fattahi H, Cicione A, *et al.* The number of cores positive for high grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy. *J Urol* 2009;**181**:1069–74.

Djavan B, Mazal P, Zlotta A, Wammack R, Ravery V, Remzi M, *et al.* Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study. *Prostate* 2001;**47**:111–17.

Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M, *et al.* Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. *J Urol* 2001;**166**:856–60.

Djavan B, Fong YK, Ravery V, Remzi M, Horninger W, Susani M, *et al.* Are repeat biopsies required in men with PSA levels < or = 4 ng/ml? A Multiinstitutional Prospective European Study. *Eur Urol* 2005;**47**:38–44.

Fleshner N, Klotz L. Role of 'saturation biopsy' in the detection of prostate cancer among difficult diagnostic cases. *Urology* 2002;**60**:93–7.

Fleshner NE, O'Sullivan M, Fair WR. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. *J Urol* 1997;**158**:505–8.

Forde JC, O'Connor KM, Casey L, O'Brien M, Bowen S, Casey RG, *et al.* A rapid access diagnostic clinic for prostate cancer: the experience after one year. *Ir J Med Sci* 2011;**180**:505–8.

Giulianelli R, Brunori S, Gentile BC, Vincenti G, Nardoni S, Shestani T, *et al.* Risk of prostate cancer at first saturation re-biopsy in a patient with previous diagnosis of HGPIN. *Arch Ital Urol Androl* 2010;**82**:172–4.

Gjengsto P, Paus E, Halvorsen OJ, Eide J, Akslen LA, Wentzel-Larsen T, *et al.* Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: a prospective institutional study. *J Urol* 2005;**173**:425–8.

- Gore JL, Shariat SF, Miles BJ, Kadmon D, Jiang N, Wheeler TM, *et al.* Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. *J Urol* 2001;**165**:1554–9.
- Grepl M, Student V, Furst T, Furstova J. Prostate cancer detection yield in repeated biopsy is independent of the diagnosis of earlier biopsies. *Biomed Pap Med Fac Palacky Univ* 2009;**153**:297–302.
- Gupta NP, Ansari MS, Dass SC. Transrectal ultrasound guided biopsy for detecting early prostate cancer: An Indian experience. *Indian J Canc* 2005;**42**:151–4.
- Gurses B, Tasdelen N, Yencilek F, Kilickesmez NO, Alp T, Firat Z, *et al.* Diagnostic utility of DTI in prostate cancer. *Eur J Radiol* 2011;**79**:172–6.
- Hadaschik BA, Kuru TH, Tulea C, Rieker P, Popeneciu IV, Simpfendorfer T, *et al.* A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion. *J Urol* 2011;**186**:2214–20.
- Halpern EJ, Ramey JR, Strup SE, Frauscher F, McCue P, Gomella LO. Detection of prostate carcinoma with contrast-enhanced sonography using intermittent harmonic imaging. *Cancer* 2005;**104**:2373–83.
- Haroun AA, Hadidy AS, Awwad ZM, Nimri CF, Mahafza WS, Tarawneh ES. Utility of free prostate specific antigen serum level and its related parameters in the diagnosis of prostate cancer. *Saudi J Kidney Dis Transplant* 2011;**22**:291–7.
- Imai K, Ichinose Y, Kubota Y, Yamanaka H, Sato J. Diagnostic significance of prostate specific antigen and the development of a mass screening system for prostate cancer. *J Urol* 1995;**154**:1085–9.
- Izawa JI, Lega I, Downey D, Chin JL, Luke PP. Do all patients with high-grade prostatic intraepithelial neoplasia on initial prostatic biopsy eventually progress to clinical prostate cancer? *BJU Int* 2005;**96**:320–3.
- Kang SG, Tae BS, Min SH, Ko YH, Kang SH, Lee JG, *et al.* Efficacy and cost analysis of transrectal ultrasound-guided prostate biopsy under monitored anesthesia. *Asian J Androl* 2011;**13**:724–7.
- Kawakami S, Kihara K, Fujii Y, Masuda H, Kobayashi T, Kageyama Y. Transrectal ultrasound-guided transperineal 14-core systematic biopsy detects apico-anterior cancer foci of T1c prostate cancer. *Int J Urol* 2004;**11**:613–18.
- Kawakami S, Okuno T, Yonese J, Igari T, Arai G, Fujii Y, *et al.* Optimal sampling sites for repeat prostate biopsy: a recursive partitioning analysis of three-dimensional 26-core systematic biopsy. *Eur Urol* 2007;**51**:675–82.
- Keetch DW, Catalona WJ. Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate-specific antigen values. *J Urol* 1995;**154**:1795–7.
- Liu JJ, Macy M, Lai YH, Terris MK. Critical evaluation of the current indications for transition zone biopsies. *Urology* 2001;**57**:1117–20.
- Matsumoto K, Satoh T, Egawa S, Shimura S, Kuwao S, Baba S. Efficacy and morbidity of transrectal ultrasound-guided 12-core biopsy for detection of prostate cancer in Japanese men. *Int J Urol* 2005;**12**:353–60.
- Miyagawa T, Ishikawa S, Kimura T, Suetomi T, Tsutsumi M, Irie T, *et al.* Real-time Virtual Sonography for navigation during targeted prostate biopsy using magnetic resonance imaging data. *Int J Urol* 2010;**17**:855–60.

- Moran BJ, Braccioforte MH. Stereotactic transperineal prostate biopsy. *Urology* 2009;**73**:386–8.
- Morote J, Planas J, Ramirez C, Gomez E, Raventos CX, Placer J, *et al.* Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk. *BJU Int* 2010;**105**:481–4.
- Netto Júnior NR, De Lima ML, Lavoura Júnior NS, Apuzzo F, De Lucena RG. A long follow-up on prostate specific antigen density and prostate biopsy. *Arch Esp Urol* 1998;**51**:1050–3.
- Ng TK, Vasilareas D, Mitterdorfer AJ, Maher PO, Lalak A. Prostate cancer detection with digital rectal examination, prostate-specific antigen, transrectal ultrasonography and biopsy in clinical urological practice. *BJU Int* 2005;**95**:545–8.
- Nomikos M, Karyotis I, Phillipou P, Constadinides C, Delakas D. The implication of initial 24-core transrectal prostate biopsy protocol on the detection of significant prostate cancer and high grade prostatic intraepithelial neoplasia. *International Braz J Urol* 2011;**37**:87–93.
- Novara G, Boscolo-Berto R, Lamon C, Fracalanza S, Gardiman M, Artibani W, *et al.* Detection rate and factors predictive the presence of prostate cancer in patients undergoing ultrasonography-guided transperineal saturation biopsies of the prostate. *BJU Int* 2010;**105**:1242–6.
- Ouzzane A, Puech P, Lemaitre L, Leroy X, Nevoux P, Betrouni N, *et al.* Combined multiparametric MRI and targeted biopsies improve anterior prostate cancer detection, staging, and grading. *Urology* 2011;**78**:1356–62.
- Ozveri H, Cam K, Tarcan T, Turkeri L, Akdas A. Early diagnosis of prostate cancer among 1181 patients attending an urology outpatient department. *J BUON* 2000;**5**:389–92.
- Pal RP, Elmussareh M, Chanawani M, Khan MA. The role of a standardized 36 core template-assisted transperineal prostate biopsy technique in patients with previously negative transrectal ultrasonography-guided prostate biopsies. *BJU Int* 2012;**109**:367–71.
- Park SJ, Miyake H, Hara I, Eto H. Predictors of prostate cancer on repeat transrectal ultrasound-guided systematic prostate biopsy. *Int J Urol* 2003;**10**:68–71.
- Patel AR, Jones JS, Rabets J, DeOreo G, Zippe CD. Parasagittal biopsies add minimal information in repeat saturation prostate biopsy. *Urology* 2004;**63**:87–9.
- Pepe P, Aragona F. Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation. *Urology* 2007;**70**:1131–5.
- Pepe P, Candiano G, Pennisi M, Aragona F. Can Sonovue targeted biopsy replace extended or saturation biopsy in prostate cancer diagnosis? Our experience at primary and repeat biopsy. *Arch Ital Urol Androl* 2010;**82**:155–9.
- Perachino M, diCiolo L, Barbetti V, Ardoino S, Vitali A, Introini C, *et al.* Results of rebiopsy for suspected prostate cancer in symptomatic men with elevated PSA levels. *Eur Urol* 1997;**32**:155–9.
- Pryor MB, Schellhammer PF. The pursuit of prostate cancer in patients with a rising prostate-specific antigen and multiple negative transrectal ultrasound-guided prostate biopsies. *Clin Prostat Cancer* 2002;**1**:172–6.
- Rabets JC, Jones JS, Patel A, Zippe CD. Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. *J Urol* 2004;**172**:94–7.

Ragde H, Kenny GM, Murphy GP, Landin K. Transrectal ultrasound microbubble contrast angiography of the prostate. *Prostate* 1997;**32**:279–83.

Rastinehad AR, Baccala AA Jr, Chung PH, Proano JM, Kruecker J, Xu S, *et al.* D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging. *J Urol* 2011;**185**:815–20.

Remzi M, Djavan B, Wammack R, Momeni M, Seitz C, Erne B, *et al.* Can total and transition zone volume of the prostate determine whether to perform a repeat biopsy? *Urology* 2003;**61**:161–6.

Roehrborn CG, Pickens GJ, Sanders JS. Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels. *Urology* 1996;**47**:347–52.

Roobol MJ, Zappa M, Maattanen L, Ciatto S. The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC). *Prostate* 2007;**67**:439–46.

Rovner ES, Schanne FJ, Malkowicz SB, Wein AJ. Transurethral biopsy of the prostate for persistently elevated or increasing prostate specific antigen following multiple negative transrectal biopsies. *J Urol* 1997;**158**:138–41.

Sajadi KP, Kim T, Terris MK, Brown JA, Lewis RW. High yield of saturation prostate biopsy for patients with previous negative biopsies and small prostates. *Urology* 2007;**70**:691–5.

Scattoni V, Roscigno M, Freschi M, Deho F, Raber M, Briganti A, *et al.* Atypical small acinar proliferation (ASAP) on extended prostatic biopsies: predictive factors of cancer detection on repeat biopsies. *Arch Ital Urol Androl* 2005;**77**:31–6.

Scattoni V, Raber M, Capitanio U, Abdollah F, Roscigno M, Angiolilli D, *et al.* The optimal rebiopsy prostatic scheme depends on patient clinical characteristics: results of a recursive partitioning analysis based on a 24-core systematic scheme. *Eur Urol* 2011;**60**:834–41.

Shigemura K, Motoyama S, Yamashita M. Do additional cores from MRI cancer-suspicious lesions to systematic 12-core transrectal prostate biopsy give better cancer detection? *Urol Int* 2012;**88**:145–56.

Singh AK, Krieger A, Lattouf JB, Guion P, Grubb RL III, Albert PS, *et al.* Patient selection determines the prostate cancer yield of dynamic contrast-enhanced magnetic resonance imaging-guided transrectal biopsies in a closed 3-Tesla scanner. *BJU Int* 2008;**101**:181–5.

Spajic B, Stimac G, Ruzic B, Trnski D, Kraus O. Prostate cancer detection in repeat extended prostate biopsy in men with previous negative biopsy findings. *Acta Clinica Croatica* 2004;**43**:117–120.

Stamatiou K, Alevizos A, Karanasiou V, Mariolis A, Mihas C, Papathanasiou M, *et al.* Impact of additional sampling in the TRUS-guided biopsy for the diagnosis of prostate cancer. *Urol Int* 2007;**78**:313–17.

Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. *J Urol* 2001;**166**:86–91.

Terris MK, Wallen EM, Stamey TA. Comparison of mid-lobe versus lateral systematic sextant biopsies in the detection of prostate cancer. *Urol Int* 1997;**59**:239–42.

Wu AK, Reese AC, Cooperberg MR, Sadetsky N, Shinohara K. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer. *Prostate Cancer Prostat Dis* 2012;**15**:100–5.

Yamamoto T, Ito K, Ohi M, Kubota Y, Suzuki K, Fukabori Y, *et al*. Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 NG/ML or less. *Urology* 2001;**58**:994–8.

Yang JB, Jeong BC, Seo SI, Jeon SS, Choi HY, Lee HM. Outcome of prostate biopsy in men younger than 40 years of age with high prostate-specific antigen (PSA) levels. *Korean J Urol* 2010;**51**:21–4.

Zangos S, Eichler K, Engelmann K, Ahmed M, Dettmer S, Herzog C, *et al*. MR-guided transgluteal biopsies with an open low-field system in patients with clinically suspected prostate cancer: technique and preliminary results. *Eur Radiol* 2005;**15**:174–82.

Zangos S, Melzer A, Eichler K, Sadighi C, Thalhammer A, Bodelle B, *et al*. MR-compatible assistance system for biopsy in a high-field-strength system: initial results in patients with suspicious prostate lesions. *Radiology* 2011;**259**:903–10.

Zhao HW, Luo JH, Xu HX, Wang DH, Lai YR, Chen MN, *et al*. The value of contrast-enhanced transrectal ultrasound in predicting the nature of prostate diseases and the Gleason score of prostate cancer by a subjective blood flow grading scale. *Urol Int* 2011;**87**:165–70.

Zippe CD, Pasqualotto FF, Sekhon V, Srivastava M, Agarwal A, Klein EA. Sextant lateral base TRUS-guided biopsy technique is superior to the sextant parasagittal technique. *J Urol* 2000;**163**:273.